CRC Trials | Aplastic Anemia & MDS International Foundation

Clinical research is at the heart of all medical advances, identifying new ways to prevent, detect or treat disease. If you have a bone marrow failure disease, you may want to consider taking part in a clinical trial, also called a research study.

CRC Trials

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination with Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms CRC

Status(es): Recruiting
Study Date(s): Friday, May 5, 2017 to Friday, May 1, 2020
Disease(s): acute myeloid leukemia (AML), chronic myelomonocytic leukaemia (CMML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)
Age Group: 18 years and older
The main purpose of the study is to determine the safe and recommended dose of APR-246 in combination with azacitidine as well as to see if this combination of therapy improves overall survival.

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms CRC

Status(es): Recruiting
Study Date(s): Tuesday, March 15, 2016 to Saturday, June 1, 2019
Disease(s): myeloproliferative neoplasms (MPN)
Age Group: 18 years and older
Open label single-arm, single-institution study to evaluate the efficacy and safety of SGI-110 in Philadelphia chromosome negative (Ph-) Myeloproliferative Neoplasms (MPN) (excluding PV, ET and primary/secondary myelofibrosis).  The study will enroll approximately 50 patients at the Weill Cornell Medical College.

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients with Myelodysplastic Syndrome (MDS) CRC

Status(es): Recruiting
Study Date(s): Friday, May 5, 2017 to Friday, May 1, 2020
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
The goal of this clinical research study is to learn if azacitidine in combination with pembrolizumab can help to control myelodysplastic syndrome (MDS).

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) CRC

Status(es): Recruiting
Study Date(s): Wednesday, October 1, 2014 to Thursday, October 1, 2026
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
The goal of this clinical research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing schedule, may help to control MDS.  The safety of each study drug given on these schedules will also be studied.